Organogenesis (NASDAQ:ORGO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Organogenesis (NASDAQ:ORGO) released its earnings results on Tuesday. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.11, Zacks reports. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. During the same quarter last year, the business posted $0.02 earnings per share. Organogenesis updated its FY 2024 guidance to EPS.

Organogenesis Price Performance

Shares of NASDAQ:ORGO traded down $0.18 during trading on Friday, hitting $3.83. 191,720 shares of the company’s stock were exchanged, compared to its average volume of 822,942. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.42. Organogenesis has a 52-week low of $2.16 and a 52-week high of $4.70. The business’s 50-day simple moving average is $2.97 and its 200 day simple moving average is $2.81. The company has a market cap of $507.78 million, a price-to-earnings ratio of -63.50 and a beta of 1.60.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.